Shirish M Gadgeel
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients (NCT04470674) | Shirish M Gadgeel | 2021-04-06 |
Track Shirish M Gadgeel automatically
Every clearance here is in the API, with alerts when new ones post.